Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study
Irritable bowel syndrome (IBS) tends to be a lifelong disorder and it is often frustrating to both patients and physicians. This study aim of improving symptom control, reducing healthcare burden and upgrading the quality of life of patient with diarrhea predominant IBS-D.
Patients of both sex of age group 18-65 years attending gastroenterology outpatient department Dhaka Medical College Hospital (DMCH) meeting the inclusion criteria of Diarrhea predominant irritable bowel syndrome (IBS-D) will be initially enrolled for the study. Their history, clinical examination & initial investigations will be done. Report will be noted in the standard data sheet. Any alternative diagnosis if proven by clinical examination or laboratory investigation will be excluded from the study.
Each patient will go through a run-in period of 7 days. Number of subjects will be recruited according to sample size. Randomization into two groups will be performed by online randomizer websites.
One group will receive tablet ramosetron 2.5 mcg one time daily at morning before breakfast while the other group will receive identical looking placebo one tablet once daily at same time. Both groups will be adviced for low FODMAP diet along with lifestyle modification. The tablets will be administered for total 4 weeks. Before starting treatment, each individual will undergo a baseline assessment during which demographic data, base line investigations, IBS symptoms by IBS Symptom Severity Score (IBS-SSS) will be recorded. Patients will be followed-up after 4 weeks and 8 weeks by IBS-SSS questionnaire. Any adverse effect will be reported quickly and documented at the same time.
IBS-SSS is a 5 item tools. It is primarily measures the IBS symptoms which includes abdominal pain and distension as well as bowel satisfaction. This scale evaluates IBS symptoms: abdominal pain, abdominal distension, stool frequency and consistency and interference with life in general. The IBS-SSS calculates the sum of these 5 items scored on a visual analogue scale from 0-100.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Dr. Md. Aminul Islam
- Numero di telefono: +8801626299434
- Email: aminulthesis0950@gmail.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Adults aged 18-65 years.
- Patients fulfilling Rome IV diagnostic criteria for IBS-D.
- Willing to provide informed written consent.
- Patients able to attend regular follow-up visits during the study period.
Exclusion Criteria:
- Presence of alarm features: anemia, weight loss, per rectal bleeding, nocturnal frequency, and family history of colonic cancer or inflammatory bowel disease
- History of major gastrointestinal surgery (excluding appendicitis )
- Recent antibiotic use within 4 weeks
- Patient with uncontrolled diabetes, hyperthyroidism, hypothyroidism
- Pregnant or lactating women
- Drug abuse or alcohol abuse
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Ramosetron 2.5 microgram
Group A - Ramosetron 2.5 microgram
|
Ramosetron 2.5 microgram will be given in Group A
|
|
Comparatore placebo: Placebo
Group B - Placebo
|
Placebo will be given in Group C
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Improvement of diarrhea predominant IBS symptoms
Lasso di tempo: At baseline before randomization and then at week 4 and week 8
|
The improvement of IBS symptoms will be assessed by IBS symptom severity score (IBS-SSS).
This score is a Likert scale with seven domains divided into two parts.
Part one is the severity score containing four domains, where domain one has two separate scoring scale.
Each scale scoring from 0 to 100, that makes it a total score of 500.
The severity is denoted as Mild (Score 75 to 175), Moderate (Score 176 to 300), and severe (Score more than 300).
The part two is a descriptive questionnaire about bowel habit
|
At baseline before randomization and then at week 4 and week 8
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The effect of ramosetron in diarrhea predominant IBS patients
Lasso di tempo: At baseline before randomization and then at week 4 and week 8
|
The improvement of IBS symptoms will be assessed by IBS symptom severity score (IBS-SSS).
This score is a Likert scale with seven domains divided into two parts.
Part one is the severity score containing four domains, where domain one has two separate scoring scale.
Each scale scoring from 0 to 100, that makes it a total score of 500.
The severity is denoted as Mild (Score 75 to 175), Moderate (Score 176 to 300), and severe (Score more than 300).
The part two is a descriptive questionnaire about bowel habit.
|
At baseline before randomization and then at week 4 and week 8
|
|
The effect of placebo in diarrhea predominant IBS patients
Lasso di tempo: At baseline before randomization and then at week 4 and week 8
|
The improvement of IBS symptoms will be assessed by IBS symptom severity score (IBS-SSS).
This score is a Likert scale with seven domains divided into two parts.
Part one is the severity score containing four domains, where domain one has two separate scoring scale.
Each scale scoring from 0 to 100, that makes it a total score of 500.
The severity is denoted as Mild (Score 75 to 175), Moderate (Score 176 to 300), and severe (Score more than 300).
The part two is a descriptive questionnaire about bowel habit.
|
At baseline before randomization and then at week 4 and week 8
|
|
Compare the effect of ramosetron and placebo
Lasso di tempo: At baseline before randomization and then at week 4 and week 8
|
The improvement of IBS symptoms will be assessed by IBS symptom severity score (IBS-SSS).
This score is a Likert scale with seven domains divided into two parts.
Part one is the severity score containing four domains, where domain one has two separate scoring scale.
Each scale scoring from 0 to 100, that makes it a total score of 500.
The severity is denoted as Mild (Score 75 to 175), Moderate (Score 176 to 300), and severe (Score more than 300).
The part two is a descriptive questionnaire about bowel habit.
|
At baseline before randomization and then at week 4 and week 8
|
|
Adverse events
Lasso di tempo: through study completion, approximately 1 year
|
Patient reported adverse events will be documented
|
through study completion, approximately 1 year
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- IRB-DMC/2025/259
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .